This is the same set of patients, but notice that the ORR is better now at 56% than the 50% achieved at interim.
In FORWARD II's combination with Bevacizumab, Mirv. S. is meant to replace the chemo component typically used with Bev. Note that FORWARD II doesn't have the same restrictions on enrollment as FORWARD I or AURELIA without requirements for FR-alpha expression or number of prior therapies; here was 3 the median number of therapies (1-8 possible) vs a maximum of 2 for AURELIA.
They achieved parity with AURELIA results overall with a sicker population and fewer side effects but were markedly superior for patients who have had fewer prior therapies and have med/high FR-alpha expression and/or were Bev. naive.